Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 21690598)

1.

Enhancing prescription drug innovation and adoption.

Alexander GC, O'Connor AB, Stafford RS.

Ann Intern Med. 2011 Jun 21;154(12):833-7, W-301. doi: 10.7326/0003-4819-154-12-201106210-00012.

2.
3.

Safe & sound. Interview by Helena Gail Rubinstein.

Woodcock J.

AHIP Cover. 2009 Mar-Apr;50(2):38-43. No abstract available.

PMID:
19385317
4.

How drugs are developed and approved by the FDA: current process and future directions.

Ciociola AA, Cohen LB, Kulkarni P; FDA-Related Matters Committee of the American College of Gastroenterology.

Am J Gastroenterol. 2014 May;109(5):620-3. doi: 10.1038/ajg.2013.407. Review.

PMID:
24796999
5.

Comparison of prescription reimbursement methodologies in Japan and the United States.

Akaho E, MacLaughlin EJ, Takeuchi Y.

J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):519-26. Review.

PMID:
12952317
6.

Preventing postmarketing changes in recommended doses and marketing withdrawals.

Peck C.

Ernst Schering Res Found Workshop. 2007;(59):209-16. Review.

PMID:
17117726
7.

Canadian and US drug approval times and safety considerations.

Rawson NS, Kaitin KI.

Ann Pharmacother. 2003 Oct;37(10):1403-8.

PMID:
14519031
8.

"Safer, but not safe enough".

Crombie HD.

Conn Med. 2006 Nov-Dec;70(10):645. No abstract available.

PMID:
17190395
9.

Prescription drugs, products liability, and preemption of tort litigation.

DeAngelis CD, Fontanarosa PB.

JAMA. 2008 Oct 22;300(16):1939-41. doi: 10.1001/jama.2008.513. No abstract available.

PMID:
18940985
10.
11.

The complexity of integrating speed and safety in drug development and approval.

Charo RA.

JAMA Intern Med. 2013 Jul 8;173(13):1165-6. doi: 10.1001/jamainternmed.2013.7161. No abstract available.

PMID:
23568604
12.

Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.

Viscusi WK, Rowland SR, Dorfman HL, Walsh CJ.

Spec Law Dig Health Care Law. 1996 Mar;(205):9-52. No abstract available.

PMID:
10156421
13.

Parental preferences for FDA-approved medications prescribed for their children.

Yoon EY, Clark SJ, Butchart A, Singer D, Davis MM.

Clin Pediatr (Phila). 2011 Mar;50(3):208-14. doi: 10.1177/0009922810385105. Epub 2010 Nov 22.

PMID:
21098519
14.
15.

Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.

Jacobson JD, Feigal D.

Food Drug Law J. 2007;62(3):529-46. No abstract available.

PMID:
17915395
16.

Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.

Lipworth W, Doran E, Kerridge I, Day R.

Aust Health Rev. 2014 May;38(2):160-8. doi: 10.1071/AH13240.

PMID:
24589424
17.

Heal the damage: prescription drug consumer advertisements and relative choices.

Gilhooley M.

J Health Law. 2005 Winter;38(1):1-44.

PMID:
15968938
18.
19.

Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.

Cohen J, Malins A, Shahpurwala Z.

Health Aff (Millwood). 2013 Apr;32(4):762-70. doi: 10.1377/hlthaff.2012.0707.

PMID:
23569057
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk